Form 4: Gilead CMO Berger Reports Stock Transactions

Gilead Sciences' Chief Medical Officer, Dietmar Berger, reported the acquisition of common stock and new equity incentives, alongside the sale of shares.

Summary

• Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc. (GILD), reported several transactions on March 10, 2026.
• Acquired 2,133 shares of common stock through the exercise of derivative securities.
• Disposed of 1,063 shares of common stock at a price of $148.56 per share, likely for tax withholding purposes.
• Acquired 2,133 Restricted Stock Units (RSUs) and an additional 8,415 Restricted Stock Units.
• Received a grant of 31,475 Non-qualified Stock Options with an exercise price of $148.56.
• Following these transactions, beneficial ownership of common stock is 18,982 shares, 47,461 Restricted Stock Units, and 31,475 Non-qualified Stock Options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive due to the significant grant of new equity incentives (RSUs and stock options) to a key executive, which aligns management's long-term interests with shareholders. The sale of shares is likely for tax purposes and is a routine event.

Positives

• The acquisition of 8,415 new Restricted Stock Units and 31,475 Non-qualified Stock Options aligns the Chief Medical Officer's interests with long-term shareholder value.
• The vesting schedules for RSUs and stock options (4-year schedule, 25% on first anniversary, then 6.25% quarterly) incentivize long-term commitment and performance.

Negatives

• The disposition of 1,063 shares of common stock, while likely for tax purposes related to RSU vesting, reduces the direct common stock holdings of the Chief Medical Officer.

Future Outlook

The newly granted Restricted Stock Units and Non-qualified Stock Options have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested. This indicates a long-term incentive structure for the Chief Medical Officer.

Management Comments

• The reported transactions reflect the Chief Medical Officer's participation in the company's equity incentive plans, aligning personal financial interests with the company's long-term performance and shareholder value.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. These transactions, particularly the grant of new equity incentives, are standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives, linking their compensation to company performance.

Stakeholder Impact

• Shareholders: The grant of new equity incentives to the Chief Medical Officer reinforces alignment between executive compensation and shareholder value creation over the long term.
• Employees: These transactions are part of standard executive compensation practices, which can influence overall employee morale and retention strategies.

Next Steps

• The Restricted Stock Units and Non-qualified Stock Options will vest over a four-year period, with the first 25% vesting on the first anniversary of the grant date (March 10, 2027) and the remainder vesting quarterly thereafter.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology, Pharmaceuticals